ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTNM vs JNJ // GROSS PROFIT MARGIN

Contineum Therapeutics Inc. (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CTNM 0 — JNJ 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTNM VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTNM JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -29.00% 25.50% -54.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -15.82% 2.97% -18.79 JNJ /fcf-yield <GO>
Operating Margin — 34.70% — TIE /operating-margins <GO>
Net Profit Margin — 28.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 6.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 8/9 -6.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.0 62.1 -19.06 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $351.0M $662.49B -$662.14B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTNM REV JNJ REV CTNM GROSS % JNJ GROSS % CTNM FCF JNJ FCF
FY 2025 $0 $94.19B — 67.9% -$55.5M $19.70B
FY 2024 $0 $88.82B — 69.1% -$33.4M $19.84B
FY 2023 $50.0M $85.16B — — $19.3M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTNM // BETA —
JNJ // BETA 1.08